Table 4.
Cox regression survival analysis showing the effects of medication use on mortality from breast cancer-specific causes and other and unknown causes.
| Medication Use | No Previous Hospitalisation | with Previous Hospitalisation^ | ||
|---|---|---|---|---|
| Crude HR (95%CI) |
Adjusted HR (95%CI) |
Crude HR (95%CI) |
Adjusted HR (95%CI) |
|
| Mortality from breast cancer-specific causes | ||||
| 1 drug | 1.09 (0.81–1.46) | 1.07 (0.77–1.47) | 0.87 (0.72–1.06) | 1.00 (0.81–1.23) |
| 2–3 drugs | 0.94 (0.67–1.30) | 0.82 (0.56–1.20) | 0.72 (0.59–0.87) *** | 0.96 (0.78–1.18) |
| ≥4 drugs | 1.01 (0.61–1.67) | 1.03 (0.58–1.83) | 0.66 (0.54–0.82) *** | 0.90 (0.71–1.14) |
| Mortality from other and unknown causes | ||||
| 1 drug | 0.66 (0.39–1.12) | 0.69 (0.39–1.20) | 0.96 (0.76–1.20) | 0.82 (0.65–1.05) |
| 2–3 drugs | 1.57 (1.04–2.36) * | 1.04 (0.65–1.65) | 1.14 (0.94–1.38) | 0.76 (0.61–0.94) ** |
| ≥4 drugs | 2.25 (1.33–3.82) ** | 0.82 (0.40–1.68) | 1.66 (1.38–1.99) *** | 0.90 (0.73–1.10) |
* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001; ^ Previous hospitalisation indicates presence of a severe comorbidity(-ies) that requires hospitalisation; the models were stratified by tumour factors such as biological type, histologic grade, anatomic stage and histology and adjusted for age, ethnicity, facility, NZDep2013, region, diagnosis to first cancer treatment duration, and screen-detected.